Inflammation: Clinical Trials

45 recruiting. 45 Phase 4.

By phase and status

Phase	Trials	Status
Phase 4	45	Recruiting 45

Follow Inflammation: new trials by email Literature Review of Inflammation trials Research Report on Inflammation

Trials (filtered) newest first · largest first

All 45 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
VATS or Intrapleural Enzymatic Therapy for Patients With Empyema. VATS group, IET - Empyema, Pleural, Pleural Infections	Phase 4	Recruiting	Amsterdam UMC	164	2026-10-01	2026-10-26
Individualized Multiplex Pathophysiological Treatment of Severe Acute Infections: N-Acetylcysteine N-Acetylcysteine (NAC) Treatment - Sepsis, Acute Infection	Phase 4	Recruiting	Theis S. Itenov	360	2026-09-07	2026-09-16
Oral Switch in Pediatric Bloodstream Infections Oral antibiotic therapy, Standard IV antibiotic therapy - Bloodstream Infection, Bacteremia Sepsis	Phase 4	Recruiting	Ulrikka Nygaard	150	2026-09-01	2026-10-19
Clinical Efficacy of Stopping Oral Antibiotics When Symptoms Stop, Compared to 'Finishing the Course' Antibiotics for duration of symptoms, Antibiotics for duration of prescribed course - Urinary Tract Infection, Cellulitis	Phase 4	Recruiting	Murdoch Childrens Research Institute	200	2026-08-18	2026-08-21
The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS) Piperacillin + Tazobactam, meropenem - Infection, Acute Kidney Injury	Phase 4	Recruiting	Bassett Healthcare	852	2026-08-17	2026-10-15
Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure Hydrocortisone Hemisuccinate: 200 mg per day., reduction of the level of immunosuppression - Sepsis and Septic Shock, Acute Respiratory Failure	Phase 4	Recruiting	University Hospital, Strasbourg, France	212	2026-08-11	2026-08-20
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) Linvoseltamab, Tocilizumab - Relapsed/Refractory Multiple Myeloma (RRMM)	Phase 4	Recruiting	Regeneron Pharmaceuticals	30	2026-07-15	2026-10-27
Anemia Therapy in Patients With Infective Endocarditis Adjunctive anemia therapy - Infective Endocarditis (IE), Severe Anemia	Phase 4	Recruiting	Copenhagen University Hospital, Rigshospitalet	74	2026-05-15	2026-05-29
Aminoglycosides in Early Sepsis Gentamicin + narrow spectrum betalactam, Cefotaxime, Piperacillin-tazobactam - Sepsis	Phase 4	Recruiting	University Hospital, Akershus	1900	2026-04-23	2026-10-28
Adjunctive Hyperbaric Oxygen Treatment for Patients With Necrotizing Soft-Tissue Infection (HOT-NSTI Trial). Hyperbaric oxygen treatment, Standard of Care (Investigator Choice) - Necrotizing Soft Tissue Infection	Phase 4	Recruiting	Ole Hyldegaard	1480	2026-04-04	2026-09-04
Hydrocortisone and Fludrocortisone for the Treatment of Septic Shock Hydrocortisone plus Fludrocortisone, Standard care - Septic Shock	Phase 4	Recruiting	Northern Jiangsu People's Hospital	336	2026-03-02	2026-03-04
Gelaspan vs Crystalloid Therapy in Sepsis Balanced Gelatin Solution, Acetate Ringer's Solution - Sepsis, Intra-Abdominal Infections	Phase 4	Recruiting	Shanghai Zhongshan Hospital	318	2026-02-13	2026-03-20
Beta-lactam Plus Levofloxacin to Enhance Therapy in Streptococcal Septicemia Beta-lactam monotherapy, Beta-lactam plus levofloxacin combination therapy - Bacteremia, Streptococcus Infection	Phase 4	Recruiting	Mahidol University	165	2026-01-08	2026-08-21
Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators Recombinant Zoster Vaccine (RZV) - Autoimmune Rheumatic Diseases	Phase 4	Recruiting	University of Sao Paulo General Hospital	200	2025-12-02	2026-03-11
Vericiguat and Reverse Remodeling Indices in Heart Failure Vericiguat, Guideline Directed Medical Therapy for Heart Failure (GDMT) - Heart Failure With Reduced Ejection Fraction (HFrEF), Chronic Heart Failure	Phase 4	Recruiting	University Medical Centre Ljubljana	70	2025-11-01	2026-09-29
Once Daily Intrapleural Enzyme Therapy in Complicated Parapneumonic Effusion or Empyema Fibrinolytic once daily, Fibrinolytic twice daily, DNA degradation once daily - Pleural Infection Bacterial, Pleural Infections	Phase 4	Recruiting	University of North Carolina, Chapel Hill	270	2025-09-11	2026-09-29
GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM semaglutide, Standard Treatment (Guideline-Based) - T2DM (Type 2 Diabetes Mellitus)	Phase 4	Recruiting	Federico II University	80	2025-09-08	2026-01-02
Effect of Empagliflozin on Inflammation Empagliflozin (SGLT2i), Placebo - CAD - Coronary Artery Disease, Inflamation	Phase 4	Recruiting	Hotel Dieu de France Hospital	100	2025-09-01	2025-12-18
Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis Meropenem, Piperacillin/Tazobactam - Sepsis, Septic Shock	Phase 4	Recruiting	Scandinavian Critical Care Trials Group	5800	2025-06-26	2025-07-03
Early Versus Late Adjunctive Vasopressin in Septic Shock vasopressin - early initiation, vasopressin - standard initiation - Sepsis, Septic Shock	Phase 4	Recruiting	The Cleveland Clinic	300	2025-04-29	2026-08-31

Showing 20 of 45. Sign in to see all of them.

Narrower conditions

Sepsis (17)  ·  Shock, Septic (11)  ·  Bacteremia (5)  ·  Infections (4)  ·  Acute Kidney Injury (2)  ·  Anemia (2)  ·  Asthma (2)  ·  Cellulitis (2)  ·  Coronary Artery Disease (2)  ·  Empyema (2)  ·  Empyema, Pleural (2)  ·  Abscess (1)  ·  Autoimmune Diseases (1)  ·  Carcinoma, Non-Small-Cell Lung (1)

Broader conditions

Pathologic Processes (45)  ·  Pathological Conditions, Signs and Symptoms (45)  ·  Infections (25)  ·  Systemic Inflammatory Response Syndrome (25)  ·  Shock (13)  ·  Sepsis (7)  ·  Bacterial Infections (6)  ·  Bacterial Infections and Mycoses (6)  ·  Respiratory Tract Diseases (6)  ·  Hemic and Lymphatic Diseases (5)  ·  Immune System Diseases (5)  ·  Signs and Symptoms (5)  ·  Suppuration (5)  ·  Cardiovascular Diseases (4)

Interventions

Meropenem (4)  ·  Piperacillin, Tazobactam Drug Combination (4)  ·  Sodium Chloride (3)  ·  Standard of Care (3)  ·  Iron (2)  ·  Therapeutics (2)  ·  Acetylcysteine (1)  ·  Albumins (1)  ·  Anti-Bacterial Agents (1)  ·  Anti-Infective Agents (1)  ·  Aztreonam (1)  ·  Budesonide (1)  ·  Cefiderocol (1)  ·  Cefotaxime (1)  ·  Clindamycin (1)

Sponsors

Murdoch Childrens Research Institute (2)  ·  University of North Carolina, Chapel Hill (2)  ·  Amsterdam UMC (1)  ·  Asan Medical Center (1)  ·  Bassett Healthcare (1)  ·  Brett A Faine (1)  ·  Cairo University (1)  ·  Copenhagen University Hospital, Rigshospitalet (1)  ·  Diakonhjemmet Hospital (1)  ·  Emory University (1)  ·  Erasmus Medical Center (1)  ·  Federico II University (1)  ·  First Affiliated Hospital of Wannan Medical College (1)  ·  Frieder Schaumburg (1)  ·  Gelb, Arthur F., M.D. (1)

Countries

United States (12)  ·  China (6)  ·  Denmark (4)  ·  Norway (4)  ·  Australia (3)  ·  Italy (3)  ·  Brazil (2)  ·  Greece (2)  ·  Lebanon (2)  ·  Malaysia (2)  ·  Netherlands (2)  ·  Poland (2)  ·  South Africa (2)  ·  South Korea (2)  ·  Spain (2)

Top investigators

Ahlem Trifi (1)  ·  Amanda Wilkins, MBBS (1)  ·  Amany M Mohamed, Ph.D (1)  ·  Arianna Di Stadio, PhD (1)  ·  Arthur F Gelb, MD (1)  ·  Binita Shah, MD (1)  ·  Changhong Miao, MD (1)  ·  Cinzia Ciccacci, PhD (1)  ·  Cristina Mussini, MD (1)  ·  Daniel Freilich, MD (1)  ·  David R Goldsmith, MD (1)  ·  Diego Piatti, PT (1)

Results publications

PMID 22560478, PMID 23537051, PMID 23932460, PMID 24290280, PMID 25950858, PMID 26343939, PMID 26717511, PMID 33558347, PMID 34582425, PMID 39024364, PMID 39443954, PMID 39669005, PMID 40119275, PMID 40738645, PMID 42674465

NIH funding

2023 (4), 2025 (2), I01CX002358 (1), R01HL157422 (1), R01MH131910 (1)